Siemens Medical Solutions USA, Inc.

Janssen Pharmaceutica Nv

Xoma Technology Ltd.

Sorrento Therapeutics, Inc.

Rayzebio, Inc.

Eli Lilly and Company

Other

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Xoma (US) LLC

Vivasor, Inc.

Covx Technologies Ireland Limited

Covx Technology Ireland, Ltd.

Rapport Therapeutics, Inc.

Xoma Corporation

Gang Chen

Wei Zhang

Dhanalakshmi Kasi

Joseph C Walsh

Hartmuth C Kolb

Vani P Mocharla

Umesh B Gangadharmath

Arnold H Horwitz

Mary Haak-Frendscho

Linda Masat

Marina Roell

Kai Chen

Tieming Zhao

Anjana Sinha

Eric Wang

Peter J H Scott

Michael K Ameriks

Qianwa Liang

Tong Zhu

Anna Katrin Szardenings

Changhui Liu

Chul Yu

Zhenwei Miao

Suchitra Ravula

Alisher B Khasanov

Chaofeng Huang

Curt A Dvorak

Heather Renee Coate

Devin M Swanson

Hong Zhang

Christine Fang Gelin

Daniel Daeik Kim

Dongpei Wu

Bradley M Savall

Susan Arangio

Ken Song

Matthew Moran

Michael Anthony Letavic

Christa C Chrovian

Brice M Stenne

Akinola Soyode-Johnson

Jason Christopher Rech

Jessica L Wall

Henry Clifton Padgett

Brian Ngo Laforteza

Afton Hiscox

Zhiyong Gao

Chunfang Xia

Bin Liu

Bing Wang

Venkata Ramana Doppalapudi

Yufeng Hong

Farhad Karimi

Terry Patrick Lebold

Curt William Bradshaw

Yanwen Fu

Jimmy T Liang

Joel Desharnais

Dingguo Liu

Brian A Duclos

Abhijit Suresh Bhat

Thomas Lee Collier

Jing-Yu Lai

Bryan Douglas Oates

Cynthia G B Berry

Heyue Zhou

John Dixon Gray

Jingyi Wang

Brock T Shireman

Lichun Wang

Jing Wang

Alexander Chucholowski

Hongmei Song

Tongtong Xue

Hong Zeng

Liang Xiao

Jeannie M Ziff

Cathy Preville

Alexander Wilhelm Chucholowski

Michael Schaefers

Liping Liu

Yan Qing

Andreas Faust

Sven Hermann

Guenter Haufe

Klaus Kopka

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Vani P Mocharia

Daniel Kurt Cashion

Emma Helen Southgate

Dylan Dalun Deng

Hong D Zhang

Fabrice Loic Jourdan

David Wei Lin

Dylan Deng

Miguel Angel Pena Piñon

Katherine Fells

The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Radiolabelled MGL PET ligands

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Azabenzimidazoles and their use as AMPA receptor modulators

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

PSMA imaging agents

Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R, RR, Rand Rare defined herein.

Monoacylglycerol lipase modulators

There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.

Drug-conjugates with a targeting molecule and two different drugs

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,

Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof

Radiolabelled MGL pet ligands

Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R, R, R, R, R, R, and Rare defined herein.

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.

Stabilized compositions of radionuclides and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Gang Chen